Impacts of Superselective Infarct-related Artery (IRA) Infusion of Tirofiban on Myocardial Reperfusion and Bleeding Complications in Acute Myocardial Infarction (AMI) Patients

Not Applicable

• Conditions: Myocardial Infarction

• Registration Number: NCT01181388
• Lead Sponsor: Beijing Anzhen Hospital

Brief Summary

Superselective IRA infusion of tirofiban may improve myocardial reperfusion and reduce bleeding complications in AMI patients.

Detailed Description

Not available

Study Timeline

• Study Start: 2010-04
• Status Verified: 2010-06
• Study First Submitted: 2010-08-11
• Study First Submitted QC: 2010-08-12
• Last Update Submitted: 2010-08-12
• Study First Posted: 2010-08-13
• Last Update Posted: 2010-08-13
• Primary Completion: 2012-04
• Study Completion: 2012-10

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

• STEMI patients
• chest pain for less than 12hr
• plan to PCI

Exclusion Criteria

• LM lesion
• stent thrombosis
• cardiac shock
• thrombocytopenia
• allergy to asprin

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Major adverse cardiovascular events	3 months after PCI	Infarct size, reinfarction, motality, et.al.
Major Adverse Cardiovascular Events	6 months after PCI	Infarct size, reinfarction, motality, et.al.

Secondary Outcome Measures

Name	Time	Method
number of participants with bleeding events	1 month	bleeding events are assessed by Thrombolysis In Myocardial Infarction(TIMI) criteria

Trial Locations

Locations (1)

the 28th division, Beijing Anzhen Hospital; 🇨🇳 Beijing, Beijing, China